Sonnet BioTherapeutics Navigates Financial Compliance Hurdles
Company Announcements

Sonnet BioTherapeutics Navigates Financial Compliance Hurdles

Sonnet BioTherapeutics Holdings (SONN) has released an update.

The Company received preliminary approval in December 2023 to sell up to $4.8 million of its New Jersey state net operating losses and executed a Sale Agreement on January 24, 2024, anticipating $4.3 million in net proceeds after fees in February 2024. Concurrently, the Company was notified by Nasdaq in December 2023 of non-compliance with the minimum stockholders’ equity requirement. However, with the expected proceeds from the Sale Agreement and cancellation of unpaid bonuses, the Company believes it now meets Nasdaq’s $2.5 million Stockholders’ Equity Requirement.

For further insights into SONN stock, check out TipRanks’ Stock Analysis page.


Price Change
S&P 500
Dow Jones
Nasdaq 100

Popular Articles